慢性,NMDARs和5-HT4Rs的组合向对压力诱导的坚持性行为和催眠症产生了扩展的行为效应
Briana K Chen1,2, Alicia Whye2,3, Louise C Matthews2,3
1Doctoral Program in Neurobiology and Behavior (NB&B), Columbia University, New York, NY, 10027, USA.
概括
结合胺 (一种NMDAR抗剂) 和普鲁卡洛普里德 (5-HT4R抗剂) 有效地减少了两性之间的压力诱导行为. 这种组合治疗对精神疾病的未来临床应用有希望.
科学领域:
- 神经科学是一个神经科学.
- 药理学 药理学是指药理学的学科.
- 精神病学是一个精神病学.
背景情况:
- 血清素 (5-HT) 和N-甲基-D-酸盐受体 (NMDARs) 涉及与压力相关的精神疾病.
- 对于应激障碍的组合治疗方法的研究有限.
研究的目的:
- 评估联合 (R,S) - 胺 (NMDAR抗剂) 和普鲁卡洛普里德 (5-HT4R抗剂) 在应激后的疗效.
- 在压力模型中评估这种组合是否比单个药物提供额外的好处.
主要方法:
- 在压力诱导后 (CFC,LH,SEFL,CORT) 两周内每周多次服用盐水,胺,普鲁卡洛普里德或组合疗法 (K+P).
- 评估药物疗效使用行为测试对恐惧,绝望,坚持和双性双性.
- 研究了组合治疗的鼻内输送.
主要成果:
- 组合K + P在减少压力诱导的行为方面表现出超出单个药物治疗的额外治疗效果.
- 两性都在联合治疗后表现出行为改善.
- 内注射K+P也被发现是有效的.
结论:
- 长期服用胺和普鲁卡洛普里德联合治疗对压力诱导的病理生理学提供了持续的益处.
- 这一策略对针对广泛的压力诱导精神疾病的临床研究具有重大潜力.
相关概念视频
Desensitization and Tachyphylaxis
1.4K
Tachyphylaxis is described as a rapid decrease in response to a drug after repeated or continuous administration of the same drug dose. It is a phenomenon where the body becomes less responsive to a particular substance or intervention over time, requiring higher doses or stronger interventions to achieve the same effect. It results from adaptive changes in the body's receptors, signaling pathways, or physiological processes that occur in response to prolonged exposure to a stimulus.
1.4K
Adrenergic Agonists: Indirect-Acting Agents
1.4K
Indirect-acting adrenergic agonists potentiate the effects of endogenous catecholamines through different mechanisms without directly binding to adrenoceptors.
One mechanism involves depleting stored catecholamines by displacing them from synaptic vesicles. These agents, known as "displacers," are transported into vesicles at the expense of noradrenaline. Examples include amphetamine and tyramine, which lack a catechol moiety, resulting in prolonged action, improved oral...
One mechanism involves depleting stored catecholamines by displacing them from synaptic vesicles. These agents, known as "displacers," are transported into vesicles at the expense of noradrenaline. Examples include amphetamine and tyramine, which lack a catechol moiety, resulting in prolonged action, improved oral...
1.4K
Drugs Affecting Neurotransmitter Release or Uptake
867
Certain drugs can affect how neurotransmitters called catecholamines, are released or taken back up in the adrenergic neuron. They can have different effects on the body's sympathetic transmission. Reserpine, a natural compound found in the Rauwolfia shrub, blocks a transporter called vesicular monoamine transporter (VMAT), which leads to a buildup of catecholamines in the cell and reduces sympathetic transmission. Another drug called guanethidine works in multiple ways, including blocking...
867
Drugs Affecting Neurotransmitter Synthesis
1.2K
Drugs affecting neurotransmitter synthesis can impact the adrenergic neuron and the synthesis of neurotransmitters. For example, α-methyltyrosine and carbidopa target specific enzymes involved in catecholamine synthesis. α-methyltyrosine inhibits the enzyme tyrosine hydroxylase, which converts tyrosine into dopamine. By blocking this enzyme, α-methyltyrosine reduces dopamine production and other catecholamines. Carbidopa, on the other hand, inhibits the enzyme dopa decarboxylase,...
1.2K
Ligand-Gated Ion Channel Receptor: Gating Mechanism
2.0K
Ligand-gated ion channels are transmembrane proteins that play a vital role in intercellular communication and functions of the nervous system. They allow the influx of ions across the membrane once the neurotransmitter binds, allowing the subsequent transmission of electrical excitation across the neurons. Other ligand-gated ion channels, like the γ-aminobutyric acid (GABA) receptor, permit anions like chloride into the cells on the binding of the GABA molecule. Their entry into the cell...
2.0K
Drugs Acting on Autonomic Ganglia: Stimulants
1.2K
Ganglionic stimulants activate NM nicotinic receptors in autonomic ganglia, falling into two categories: nicotine mimetics [e.g., lobeline, dimethylpiperazine, tetramethylammonium] and muscarinic receptor agonists [e.g., muscarine, methacholine]. The first category's action is rapid and blocked by nicotinic receptor antagonists, while the second category's action is delayed and blocked by atropine-like agents. Nicotine, an alkaloid, affects the heart rate by stimulating...
1.2K


